

STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL

USAN (jk-53) LENACAPAVIR SODIUM


PRONUNCIATION len" a kap' a vir

THERAPEUTIC CLAIM Treatment of HIV-1 infection

CHEMICAL NAMES

1. *1H-Cyclopropa[3,4]cyclopenta[1,2-c]pyrazole-1-acetamide, N-[(1S)-1-[3-[4-chloro-3-[(methylsulfonyl)amino]-1-(2,2,2-trifluoroethyl)-1H-indazol-7-yl]-6-[3-methyl-3-(methylsulfonyl)-1-butyn-1-yl]-2-pyridinyl]-2-(3,5-difluorophenyl)ethyl]-5,5-difluoro-3b,4,4a,5-tetrahydro-3-(trifluoromethyl)-, sodium salt (1:1), (3bS,4aR)-* (Source: CAS)
2. *N-[(1S)-1-{3-[4-chloro-3-(methanesulfonamido)-1-(2,2,2- trifluoroethyl)-1H-indazol-7-yl]-6-[3-(methanesulfonyl)-3-methylbut-1-yn-1-yl]pyridin-2-yl}-2-(3,5-difluorophenyl)ethyl]-2- [(3bS,4aR)-5,5-difluoro-3-(trifluoromethyl)-3b,4,4a,5-tetrahydro1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl]acetamide, sodium salt (1:1)* (Source: WHO pINN list 121)

STRUCTURAL FORMULA



MOLECULAR FORMULA $C_{39}H_{31}ClF_{10}N_7O_5S_2.Na$

MOLECULAR WEIGHT 990.3

TRADEMARK None as yet

SPONSOR Gilead Sciences, Inc.

CODE DESIGNATIONS GS-HIV Na; GS-6207-02

CAS REGISTRY NUMBER 2283356-12-5

UNII BDT58WJ9WE

bww